BottomBounce
3週前
⭐ 1. Trump administration moved to reclassify cannabis to Schedule III
This is the biggest positive cannabis news connected to Trump in years.
The Trump administration initiated a major federal shift by moving cannabis from Schedule I ? Schedule III, recognizing medical use and easing restrictions.
This change expands medical research, opens banking pathways, and removes IRS 280E restrictions for cannabis businesses.
DOJ announced that FDA-approved marijuana products and state-licensed medical marijuana products are now placed in Schedule III immediately.
An expedited federal hearing is scheduled to consider broader rescheduling.
Why this is positive:
It’s the largest federal cannabis policy shift in decades, enabling research, lowering tax burdens, and improving industry stability.
⭐ 2. Trump’s executive order expanded medical marijuana & CBD research
Trump issued an Executive Order (Dec 18, 2025) directing agencies to expand research into medical marijuana and cannabidiol.
DOJ and DEA actions were explicitly framed as delivering on Trump’s promise to expand medical access and research.
Why this is positive:
It signals White House-level support for medical cannabis research and regulatory modernization.
⭐ 3. California cannabis regulators implementing rules to benefit businesses under Trump’s rescheduling
California’s Department of Cannabis Control proposed emergency rules to help businesses take advantage of federal benefits created by Trump’s rescheduling move.
Why this is positive:
States are already adjusting regulations to align with Trump’s federal changes, which could streamline licensing and compliance.
⭐ 4. Federal recognition of state-regulated medical marijuana programs
DOJ acknowledged the legitimacy of state medical marijuana systems, integrating them into the new Schedule III framework.
Why this is positive:
This reduces federal-state conflict and gives medical cannabis programs greater legal stability.
⭐ 5. Older adults increasingly turning to cannabis for medical use
While not directly Trump-driven, this trend is happening after the administration’s rescheduling move:
A federally funded AMA study found older adults are increasingly using cannabis as an alternative to pharmaceuticals.
Why this is positive:
It shows growing mainstream acceptance of cannabis for medical purposes.
⭐ 6. Federal study shows cannabis legalization reduces opioid poisonings
A federally funded study found marijuana legalization is associated with significant reductions in non-fatal opioid poisonings.
Why this is positive:
Supports the argument that cannabis access has public-health benefits, strengthening the case for reform.
⭐ 7. Trump’s rescheduling move is prompting states to modernize cannabis rules
Examples include:
California’s emergency rules (mentioned above).
Oklahoma requiring DEA registration for medical cannabis businesses to align with federal changes.
Why this is positive:
Federal action is pushing states toward more consistent, regulated, and legitimized cannabis markets. $TLRY
BottomBounce
4週前
$TLRY Tilray is active across a broad set of international cannabis markets. Based on verified sources, the countries and regions involved include Canada, Europe (multiple countries), Australia, New Zealand, and Latin America, with specific production or distribution hubs in Germany, Portugal, and the United Kingdom.
🌍 Key Regions Where Tilray Operates
Each region below is a country or market where Tilray has either cultivation, production, distribution, or export activity.
Canada — Tilray’s original base and one of its largest production footprints, including major facilities like Aphria One and Aphria Diamond.
Europe — A major strategic region with EU-GMP facilities in Portugal and Germany, plus operations in the United Kingdom, and distribution into countries such as Poland and Italy.
Australia — Part of Tilray’s medical cannabis export network.
New Zealand — Included in Tilray’s Asia-Pacific footprint.
Latin America — Tilray exports medical cannabis products into multiple Latin American markets.
🇪🇺 Why Europe Is Considered the “Sleeping Giant”
Europe is poised for major cannabis expansion due to:
Large population and growing medical cannabis demand
Increasing acceptance and regulatory movement toward broader legalization
Tilray’s early investment in EU-GMP facilities in Portugal and Germany, giving it a compliant supply chain ready for scale
Tilray has explicitly positioned itself to lead once broader EU legalization occurs.
BottomBounce
4週前
$TLRY $MJ $TOKE ⭐ 1. Trump administration moved to reclassify cannabis to Schedule III
This is the biggest positive cannabis news connected to Trump in years.
The Trump administration initiated a major federal shift by moving cannabis from Schedule I ? Schedule III, recognizing medical use and easing restrictions.
This change expands medical research, opens banking pathways, and removes IRS 280E restrictions for cannabis businesses.
DOJ announced that FDA-approved marijuana products and state-licensed medical marijuana products are now placed in Schedule III immediately.
An expedited federal hearing is scheduled to consider broader rescheduling.
Why this is positive:
It’s the largest federal cannabis policy shift in decades, enabling research, lowering tax burdens, and improving industry stability.
⭐ 2. Trump’s executive order expanded medical marijuana & CBD research
Trump issued an Executive Order (Dec 18, 2025) directing agencies to expand research into medical marijuana and cannabidiol.
DOJ and DEA actions were explicitly framed as delivering on Trump’s promise to expand medical access and research.
Why this is positive:
It signals White House-level support for medical cannabis research and regulatory modernization.
⭐ 3. California cannabis regulators implementing rules to benefit businesses under Trump’s rescheduling
California’s Department of Cannabis Control proposed emergency rules to help businesses take advantage of federal benefits created by Trump’s rescheduling move.
Why this is positive:
States are already adjusting regulations to align with Trump’s federal changes, which could streamline licensing and compliance.
⭐ 4. Federal recognition of state-regulated medical marijuana programs
DOJ acknowledged the legitimacy of state medical marijuana systems, integrating them into the new Schedule III framework.
Why this is positive:
This reduces federal-state conflict and gives medical cannabis programs greater legal stability.
⭐ 5. Older adults increasingly turning to cannabis for medical use
While not directly Trump-driven, this trend is happening after the administration’s rescheduling move:
A federally funded AMA study found older adults are increasingly using cannabis as an alternative to pharmaceuticals.
Why this is positive:
It shows growing mainstream acceptance of cannabis for medical purposes.
⭐ 6. Federal study shows cannabis legalization reduces opioid poisonings
A federally funded study found marijuana legalization is associated with significant reductions in non-fatal opioid poisonings.
Why this is positive:
Supports the argument that cannabis access has public-health benefits, strengthening the case for reform.
⭐ 7. Trump’s rescheduling move is prompting states to modernize cannabis rules
Examples include:
California’s emergency rules (mentioned above).
Oklahoma requiring DEA registration for medical cannabis businesses to align with federal changes.
Why this is positive:
Federal action is pushing states toward more consistent, regulated, and legitimized cannabis markets.
BottomBounce
1月前
$TLRY 🚀 The Tilray Bull Case — 🔥🌿
1. Cannabis Isn’t a Trend — It’s a Global Legalization Supercycle
Cannabis is marching toward legalization the same way alcohol did a century ago — slowly, then suddenly.
🌍 Macro tailwinds are lining up:
🇺🇸 U.S. rescheduling momentum is the strongest it’s ever been
🏛️ Bipartisan support for banking reform is growing
🌐 Global legalization expanding across Europe + LATAM
💰 Billions in tax revenue incentives for governments
📈 Consumer demand rising across medical + adult-use markets
This isn’t a maybe — it’s a global regulatory megatrend.
2. Tilray Is One of the Only Truly Global Cannabis Companies
Most cannabis companies are regional.
Tilray? Tilray is international.
🌎 Global footprint includes:
Canada
U.S. (via CPG + alcohol)
Europe
Australia
LATAM
Tilray has distribution, infrastructure, and regulatory positioning that most competitors can’t touch.
3. Tilray’s Diversification Is a Strategic Moat
Tilray isn’t just a cannabis company — it’s a multi-platform consumer powerhouse.
🔥 Diversified revenue streams include:
Cannabis
Medical cannabis
Hemp
Wellness
Craft beer
Beverages
CPG brands
This diversification gives Tilray something rare in the sector: stability + optionality.
4. The Alcohol Portfolio Is a Hidden Growth Engine
Tilray quietly became one of the largest craft-beer players in the U.S.
🍺 Why this matters:
Alcohol is a $200B+ market
Strong margins
National distribution
Cross-branding opportunities with cannabis
A platform for future THC beverages when regulations allow
This is a long-term Trojan horse into the U.S. cannabis market.
5. Tilray Is Positioned for U.S. Legalization Without Touching THC
Tilray has built a U.S. presence without violating federal law.
🧩 Strategic advantages:
Alcohol distribution
Hemp + wellness brands
CPG infrastructure
Retail relationships
Ability to flip the switch when legalization hits
When U.S. federal reform happens, Tilray is already in the building.
6. Europe Is Tilray’s Secret Weapon
While everyone watches the U.S., Europe is quietly becoming the world’s largest medical cannabis market.
🇪🇺 Tilray’s European advantages:
EU-GMP facilities
Medical distribution across multiple countries
First-mover advantage
Regulatory tailwinds
Potential for adult-use expansion
Tilray is one of the few companies positioned to dominate Europe.
7. Cannabis Touches Multiple Multi-Billion-Dollar Markets
Cannabis isn’t one industry — it’s a constellation of industries.
🚀 Tilray has exposure to:
Medical cannabis
Adult-use cannabis
Beverages
Wellness
Hemp
Pharmaceuticals
THC beverages (future)
CBD products
International medical markets
Each vertical is a massive opportunity on its own.
8. Tilray’s Valuation Is Crushed vs. Its Long-Term Optionality
Tilray is priced like the cannabis industry is dead — which is exactly why bulls see asymmetric upside.
💥 Why the setup is compelling:
Market cap deeply discounted
Cannabis sentiment near cycle lows
High short interest = potential squeeze fuel
Any regulatory progress could re-rate the entire sector
Diversified revenue reduces downside risk
This is the classic “left-for-dead” setup that contrarians love.
9. Tilray Is Cutting Costs + Focusing on Profitability
Execution is improving — and that’s where the upside begins.
📊 Operational improvements include:
Cost reductions
Streamlined operations
Better capital allocation
Margin expansion in alcohol + CPG
Focus on sustainable growth
Even moderate execution improvements could shift sentiment dramatically.
10. Cannabis Legalization Is Inevitable
The world is moving toward cannabis legalization — slowly, then all at once.
🔑 Why cannabis is a must:
Massive tax revenue potential
Strong public support
Medical benefits gaining recognition
Criminal justice reform momentum
Global regulatory convergence
Cannabis is a when, not an if — and Tilray is positioned to ride the wave.
Zenos Arrow
1月前
I think in the medical, R&D space, it is better. Especially the data repository from Tilray's early entrance and of course, the amount of product that can be leveraged for clinical trials. Unfortunately, we're probably a year out from realizing this advantage. Did you jump back in or are you still waiting? Absent any material news, this will to lower.
BottomBounce
2月前
🚀 1. Tilray Is One of the Only Truly Global Cannabis Companies
Tilray operates in:
Canada
United States
Europe
Australia
Latin America
Most cannabis companies are regional.
Tilray is international — and that’s a massive advantage as global legalization accelerates.
🌍 2. Tilray Has the Largest Global Cannabis Footprint
Tilray has:
EU-GMP certified facilities
Distribution across multiple continents
Medical cannabis operations in Europe
Recreational operations in Canada
Strategic U.S. assets ready for federal reform
This global infrastructure is extremely difficult for competitors to replicate.
🍺 3. Tilray Is Quietly Becoming a Major U.S. Beverage Player
Tilray owns or controls:
SweetWater Brewing
Montauk Brewing
Alpine Beer
Green Flash
Breckenridge Distillery
This gives Tilray:
U.S. revenue
U.S. distribution
U.S. shelf space
U.S. brand presence
All BEFORE cannabis becomes federally legal.
🧩 4. Tilray’s Beverage Strategy Is a Genius Trojan Horse
When U.S. legalization hits, Tilray already has:
Breweries
Distilleries
Distribution networks
Retail relationships
Manufacturing capacity
They can flip the switch and instantly launch THC beverages nationwide.
💊 5. Tilray Is a Leader in Medical Cannabis in Europe
Europe is the next big cannabis market.
Tilray is already:
EU-GMP certified
Selling medical cannabis in multiple countries
Positioned for German adult-use expansion
Building relationships with pharmacies and regulators
This is a multi-billion-dollar opportunity.
🧱 6. Tilray Has a Diversified Revenue Model
Tilray generates revenue from:
Cannabis
Beverages
Wellness products
Hemp foods
Medical exports
International operations
This diversification gives Tilray stability and multiple growth engines.
🌱 7. Tilray Is One of the Largest Cannabis Producers in the World
Tilray has:
Massive cultivation capacity
Low-cost production
Scalable infrastructure
Strong supply chain control
This positions Tilray to dominate as demand grows.
🧪 8. Tilray Has Deep Pharmaceutical-Grade Expertise
Tilray’s EU-GMP certification means:
Pharmaceutical-grade quality
Access to medical markets
Ability to supply hospitals and pharmacies
High regulatory trust
This is a moat few cannabis companies have.
🏛️ 9. Tilray Is Perfectly Positioned for U.S. Federal Legalization
When legalization hits, Tilray already has:
U.S. brands
U.S. distribution
U.S. manufacturing
U.S. retail relationships
Tilray is one of the few Canadian LPs with a real U.S. strategy.
📦 10. Tilray Is Building a Consumer Packaged Goods Empire
Tilray’s portfolio includes:
Cannabis
Beverages
Wellness
Hemp foods
Lifestyle brands
This is a long-term, durable business model.
🧠 11. Tilray’s Management Team Is Battle-Tested
CEO Irwin Simon has:
Built billion-dollar consumer brands
Led large CPG companies
Executed major acquisitions
Navigated complex regulatory environments
This is the kind of leadership cannabis companies need.
🧨 12. Tilray Has Massive Asymmetric Upside
If:
U.S. legalizes
Europe expands
Cannabis beverages explode
Global markets open
…Tilray becomes one of the biggest players in the world.
🔥 13. Tilray Is a Pure Play on Global Cannabis Normalization
As more countries legalize:
Medical markets grow
Adult-use markets open
Export markets expand
Pharmaceutical demand increases
Tilray is positioned to benefit from every stage.
🌟 14. Tilray Has Strong Brand Power
Tilray owns or partners with:
Good Supply
Broken Coast
RIFF
SweetWater
Montauk
Breckenridge
These brands give Tilray cultural relevance and consumer loyalty.
🧩 15. Tilray Is Building the Infrastructure for the Next Decade
Tilray is investing in:
Manufacturing
Distribution
Global supply chains
Brand development
R&D
This is long-term, strategic positioning.
🚀 16. Tilray Is One of the Few Cannabis Companies With Real Scale
Scale matters in cannabis:
Lower costs
Better margins
Stronger distribution
More negotiating power
Tilray is already operating at global scale.
🌐 17. Tilray Is a Bet on the Entire Cannabis Megatrend
If you believe:
Cannabis will be federally legal
Cannabis beverages will explode
Europe will legalize
Global markets will open
Medical cannabis will expand
…then Tilray is one of the clearest, purest ways to express that view.
BottomBounce
2月前
$TLRY 🥤 XMG (Flagship THC Beverage Line)
XMG is Tilray’s leading THC drink brand in Canada and the core of its cannabis beverage portfolio.
Typical products include:
XMG Cream Soda (10mg THC)
XMG Cherry Cola and Orange Soda (10mg THC)
XMG+ Tropical Cream Float (THC combined with CBG and caffeine)
XMG Atomic Sours (flavors like Cherry Lime and Foggy Peaches)
Most XMG beverages contain about 10mg of THC per can and are formulated for fast onset using nano-emulsified technology. The lineup is designed in familiar soda and energy drink formats, making it approachable for recreational use.
XMG is considered the dominant brand in Tilray’s beverage segment and ranks among the top-selling cannabis drink lines in the Canadian market.
🍺 Mollo (Alcohol Alternative Line)
Mollo is positioned as Tilray’s direct attempt to replace traditional alcohol with THC-based beverages.
Key examples include:
Mollo 10, a THC-infused lager-style drink (10mg THC)
Mollo Pineapple Seltzer (THC combined with CBG)
Mollo Orchard Chill’r, styled after cider-like drinks
These products are designed to replicate the taste and social experience of beer or cider, but with THC instead of alcohol. The goal is to offer a familiar drinking format while delivering a cannabis-induced effect rather than intoxication from alcohol.
🇺🇸 U.S. THC Beverages (Hemp-Derived Products)
Tilray is also expanding into the U.S. market through hemp-derived THC beverages, where regulations allow.
Key brands include:
Happy Flower, offering THC-infused cocktails such as margarita and bellini-style drinks
Fizzy Jane’s, a line of THC sparkling seltzers
These beverages typically contain around 5–10mg of delta-9 THC derived from hemp and are sold in select U.S. markets. Their formats closely resemble alcoholic beverages, such as cocktails and flavored seltzers.
🧠 Strategic Positioning
Tilray’s THC beverage portfolio is not just about cannabis drinks—it reflects a broader strategy to build a new category centered on alcohol replacement.
Each brand serves a specific role:
XMG focuses on fun, soda-style THC experiences
Mollo targets beer and cider substitution
Happy Flower and Fizzy Jane’s mimic cocktails and social alcohol drinks
The company is ultimately betting on the long-term shift toward “mindful drinking,” where consumers reduce alcohol consumption in favor of alternative intoxicating beverages like THC drinks.
BigPharmaKills1
2月前
I agree, cannabis has a strong future. People are sick of big pharma drugs that have side effects worse than the ailments. That's absolutely insane, and it's why people want better options like cannabis. However, big pharma is a very major industry and they have a lot of power in Washington and Wall Street and they aren't going down without a fight. They delayed re-scheduling for as long as they could and now they (along with dirty Wall Street institutions, dirty hedge funds and dirty market makers) are crushing the cannabis sector right after the biggest catalyst in cannabis history! It's criminal manipulation at the highest level. It's cartel level shit. They have no fear of any regulations, laws or government authority. They are sending the deadly message to any investor who wants to support the cannabis sector that they will be crushed! Those filthy criminals must be locked up!
The question is, how long can they keep it up? Despite what many people say, institutions CAN invest in cannabis while in Schedule 3. Also, the Democrats have stated that they will legalize cannabis so the Republicans will have to beat them to it, meaning that cannabis will be legalized in the next 2.5 years. I can wait that long.
BottomBounce
2月前
🌍 Global Cannabis Market Value & Growth Outlook
📈 Explosive Market Expansion
Across multiple independent industry forecasts, the cannabis market is growing at double-digit to high-double-digit annual rates, depending on the segment and methodology.
Here are the most authoritative figures:
$102.7B global market value in 2025, projected to reach $1.43 trillion by 2034 at a 34% CAGR.
Another global model estimates $14.1B in 2024, growing to $70.17B by 2034 at 17.4% CAGR.
A third forecast projects $134B in 2026, rising to $831B by 2035 at a 34% CAGR.
Additional analysis shows $38B in 2025, expected to reach $179.9B by 2034 at 18.8% CAGR.
Another long-term model projects $38.8B in 2025 growing to $159.8B by 2035 at 15.2% CAGR.
Synthesis:
Even though methodologies differ, every major forecast agrees:
➡️ Cannabis is one of the fastest-growing global industries, with projected growth ranging from 15% to 34% annually over the next decade.
🌎 Where Demand Is Coming From
🇺🇸 North America Leads
North America accounts for 40–84% of global market share depending on the model.
The U.S. alone is projected to reach over $428B by 2032 in some forecasts.
Recreational use drives 52–56% of U.S. demand, while medical use accounts for 42–44%.
🇪🇺 Europe Rising
Europe contributes 25–28% of global growth.
Medical cannabis adoption is accelerating due to regulatory reforms and healthcare integration.
🌏 Asia-Pacific Emerging
Asia-Pacific accounts for 20–21% of global growth.
Thailand’s full decriminalization in 2022 accelerated regional momentum.
🌍 Middle East, Africa & Latin America
These regions collectively contribute 10% of global growth.
Many countries are legalizing medical cannabis and exploring cannabis-based economic development.
💡 What’s Driving Global Demand?
1️⃣ Legalization Momentum
Over 50+ countries now allow medical cannabis, and many are moving toward recreational frameworks.
2️⃣ Medical Adoption
Cannabis is increasingly used for:
chronic pain
neurological disorders
cancer-related symptoms
appetite stimulation
anxiety and sleep disorders
3️⃣ Consumer Wellness Trends
58% of consumers prefer natural cannabis-based wellness products.
Edibles, oils, and concentrates are rapidly growing categories.
4️⃣ Product Innovation
Growth in edibles, beverages, skincare, and pharmaceutical formulations.
30% of new innovation comes from edibles and skincare.
5️⃣ Economic Opportunity
Cannabis legalization boosts job creation and tax revenue.
Many countries view cannabis as a strategic agricultural and pharmaceutical sector.
🔮 Bottom Line
Global cannabis demand is accelerating, driven by legalization, medical acceptance, wellness trends, and product innovation. Depending on the model, the market is on track to reach $150B to over $1.4T within the next decade. $TLRY
BottomBounce
2月前
The cannabis sector has some of the strongest long-term bullish forces of any emerging industry, driven by legalization momentum, massive consumer demand, and explosive market growth projections.
Below is a structured, deeply grounded, highly bullish outlook on cannabis stocks in general, with all claims supported by current industry data.
🌱 Why the Cannabis Sector Has Enormous Bullish Potential
1. Legalization Momentum Is Accelerating
The U.S. cannabis market is already enormous and is projected to grow at 11.5% annually through 2030, driven by expanding medical and recreational legalization.
Rescheduling efforts at the federal level have gained traction, with executive action pushing cannabis toward Schedule III, a shift industry leaders call a “game changer.”
More states are preparing to legalize adult-use markets, with large states like Florida and Pennsylvania expected to significantly boost national sales.
Bullish takeaway: Regulatory barriers are falling, and every new state that legalizes adds billions in potential revenue.
2. The Market Size Is Massive — and Growing Fast
The U.S. cannabis market was valued at $38.5 billion in 2024 and is projected to expand rapidly through 2030.
Global cannabis markets are even more explosive, expected to grow from $137.7 billion in 2026 to over $1.4 trillion by 2034 — a staggering 34% CAGR.
U.S. regulated cannabis sales alone are forecast to reach $39.1 billion by 2029.
Bullish takeaway: Few industries on Earth have trillion-dollar trajectories with this level of consumer demand and regulatory tailwinds.
3. Consumer Demand Is Deep, Diverse, and Expanding
Nearly half of U.S. adults have tried cannabis, reflecting broad cultural acceptance.
Demand spans medical, wellness, recreational, and specialty products — from flower to edibles to vapes to minor cannabinoids like CBN and CBG.
Pre-rolls and convenient formats are experiencing double-digit growth as mainstream consumers enter the market.
Bullish takeaway: Cannabis is no longer niche — it’s a normalized consumer category with accelerating adoption.
4. Medical Cannabis Is a Major Long-Term Growth Engine
Cannabis is increasingly used for chronic pain, chemotherapy-related nausea, and seizure disorders.
FDA-approved cannabis-derived medications (like Epidiolex) validate the plant’s therapeutic value.
As research expands, new medical applications will unlock additional multi-billion-dollar markets.
Bullish takeaway: Medical cannabis is still in early innings, with huge upside as clinical research expands.
5. Institutional Capital and Startups Are Flooding In
Major investment funds and private equity groups are deploying capital into cannabis infrastructure, cultivation, and retail.
Startups continue to raise large rounds, including $350 million+ financings for cannabis tech platforms.
Bullish takeaway: Smart money is positioning early for the next decade of growth.
6. International Legalization Is Creating a Global Opportunity
Countries across Europe, Asia, and Latin America are moving toward medical or recreational legalization.
Thailand’s full decriminalization of cannabis cultivation and consumption demonstrates how quickly markets can open and scale.
Bullish takeaway: Cannabis is becoming a global commodity, not just a U.S. trend.
🌿 Final Bullish Summary
The cannabis industry is supported by explosive market growth, broad consumer adoption, medical validation, and rapid legalization momentum. Despite short-term volatility, the long-term trajectory is unmistakably upward. The combination of regulatory reform, cultural acceptance, and trillion-dollar global potential makes cannabis one of the most compelling emerging sectors of the next decade. $TLRY
BottomBounce
2月前
$TLRY 🚀 **40 Ultra-Bullish Pillars for Tilray ($TLRY)**
*(All grounded in sourced facts; each can be expanded into 5–10 sub-reasons to reach 200.)*
### 🇨🇦 **1–10: Dominance in Canada (the world’s largest federally legal market)**
1. **#1 market share in Canada across multiple categories** including flower, pre-rolls, beverages, chocolate edibles, and oils. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
2. **Canadian cannabis revenue up 8% YoY**, showing stability and growth. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
3. **Strong brand portfolio** with leadership positions across THC categories.
4. **Regulatory moat** — Canada’s strict rules make it hard for new entrants.
5. **Tilray’s scale advantage** gives it superior distribution.
6. **Cost efficiencies** from Project 420. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
7. **45%+ THC beverage market share** — a massive moat. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
8. **Improved retail distribution** after 2025 resets. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
9. **Brand loyalty improving** as restrictions ease.
10. **Canadian leadership positions TLRY for U.S. entry** when allowed.
---
### 🌍 **11–20: Explosive International Growth**
11. **Record international cannabis revenue**, up **70% YoY**. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
12. **International revenue now 37% of total** — diversifying away from Canada. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
13. **Largest global medical cannabis footprint** among Canadian LPs.
14. **European medical cannabis expansion** accelerating.
15. **UK craft beer acquisition (BrewDog)** expands brand presence. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
16. **Carlsberg partnership** accelerates global beverage scaling. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
17. **MEA (Middle East & Africa) beverage expansion** underway. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
18. **Global distribution platform worth $300M** ready for U.S. medical entry. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
19. **Global medical cannabis TAM expanding rapidly**.
20. **Tilray positioned as a first-mover in multiple continents**.
---
### 🍺 **21–30: Beverage Empire = Hidden Growth Engine**
21. **Beverage revenue up 22% YoY** in latest quarter. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
22. **Massive synergy potential** with Carlsberg.
23. **SweetWater, Shock Top, and other brands improving** after resets. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
24. **$27M annualized cost savings** from Project 420. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
25. **Non-alcoholic category expansion** (Runner’s High). [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
26. **Beverages provide diversification** away from cannabis volatility.
27. **Beverage margins improving** with SKU rationalization.
28. **U.S. distribution footprint already built** for future THC beverages.
29. **Beverages create brand familiarity pre-legalization**.
30. **Beverage business alone could justify a higher valuation**.
---
### 🇺🇸 **31–40: U.S. Rescheduling = Massive Asymmetric Upside**
31. **Schedule III reclassification speculation already pumped TLRY 10–14%** in two days. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
32. **Federal tax advantages unlocked** under Schedule III. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
33. **Banking access improves**, lowering friction costs. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
34. **Easier compliance ? higher earnings quality**. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
35. **Tilray doesn’t even need U.S. THC sales to benefit** — optionality without risk. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
36. **CEO Irwin Simon says rescheduling is “transformative.”** [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
37. **Tilray already has a $150M global medical cannabis business** ready to plug into the U.S. market. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
38. **Analysts modeling >40% upside** (Roth Capital). [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
39. **Consensus rating: Strong Buy** with extreme upside targets (avg $72). [Stock Analysis](https://stockanalysis.com/stocks/tlry/forecast/)
40. **Asymmetric risk/reward** — downside limited, upside enormous.
BottomBounce
2月前
🔥 Why $TLRY Could See a Short Squeeze
1. High Short-Interest Percentage (8.8%–12.4% of the float)
Recent datasets show that 8.86% of TLRY’s float is sold short as of November 2025 .
Another dataset shows 12.36% short interest as of March 2026 .
Anything above 10% is considered elevated, and TLRY frequently sits near or above that threshold.
This means a meaningful portion of traders are betting against the stock — a setup that can unwind quickly.
2. Days-to-Cover Is Rising (5.95–7.57 Days)
Days-to-cover (DTC) measures how long it would take shorts to exit if they all had to buy back shares.
5.95 days as of March 31, 2026
7.57 days in the February 27, 2026 FINRA report
A DTC above 5 is considered high.
A DTC above 7 is considered squeeze-prone.
This means shorts cannot exit quickly if buying pressure increases.
3. Borrow Fees Are Elevated (8–11%)
Borrow fees for TLRY have been consistently high, with recent readings around 8.65% and spikes above 10% .
High borrow fees indicate:
Shorting TLRY is expensive
Shorts are under pressure to close positions sooner
Any upward move can force covering
This is classic squeeze fuel.
4. TLRY Has a History of Short-Driven Volatility
Historical data shows periods where TLRY had:
17% short interest
5.2–7.0 days to cover
Massive volume spikes
These conditions have previously led to sharp upside moves, especially during cannabis-sector news cycles.
This pattern increases the probability of future squeezes.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Monroe1
2月前
maynerd
2月前
CA Market News
2月前
メールアドレスで登録
